|Articles|October 12, 2020
Assessing Multiple Critical Quality Attributes of Monoclonal Antibody and Comparability Assessments
Author(s)Agilent Technologies
Discover how LC/MS peptide mapping can be used to characterize and quantify different monoclonal antibody (mAb) critical quality attributes (CQAs).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
